asa 81mg

2
NURS 2516 Clinical Medications Worksheets (You will need to make additional copies of these forms) Generic Name ASA Trade Name Bayer Aspirin Classificati on Salicylates Dose 81 mg Dosage range: 1 baby asparin daily for decreased platelet aggregation Route po Time/ frequency 0900 qd Peak 1-3 hr Onset 5-30 min Duration 3-6 hr For IV meds, compatibility with IV drips and /or solutions N/A Mechanism of action and indications (Why med ordered) Decreases platelet aggregation, indicated for prevention of DVT/PE Nursing Implications (what to focus on) Contraindications/warnings/interactions Hypersensitivity to aspirin, tartrazine (FDC yellow dye #5), or other salicylates Cross-sensitivity with other NSAIDs may exist (less with nonaspirin salicylates) Bleeding disorders or thrombocytopenia (more important with aspirin) Common side effects dyspepsia, epigastric distress, heartburn, nausea Interactions with other patient drugs, OTC or herbal medicines (ask patient specifically) Lanoxin (may increase the risk for bleeding) Lab value alterations caused by medicine May cause ↑ serum AST, ALT, and alkaline phosphatase, especially when plasma concentrations exceed 25 mg/100 ml. May alter results of serum uric acid, urine vanillylmandelic acid (VMA), protirelin-induced thyroid-stimulating hormone (TSH), urine hydroxyindoleacetic acid (5-HIAA) determinations, and radionuclide thyroid imaging. May cause ↓ serum potassium and cholesterol concentrations. Be sure to teach the patient the following about this medication Advise patients receiving aspirin prophylactically to take only prescribed dose. Increasing the dose has not been found to provide additional benefits. Instruct patient to take salicylates with a full glass of water and to remain in an upright position for 15-30 min after administration.

Upload: cassie

Post on 11-Apr-2015

1.699 views

Category:

Documents


5 download

TRANSCRIPT

NURS 2516 Clinical Medications Worksheets(You will need to make additional copies of these forms)

Generic NameASA

Trade NameBayer Aspirin

ClassificationSalicylates

Dose81 mgDosage range:1 baby asparin daily for decreased platelet aggregation

Routepo

Time/frequency0900 qd

Peak1-3 hr

Onset5-30 min

Duration3-6 hr 

For IV meds, compatibility with IV drips and /or solutionsN/A

Mechanism of action and indications(Why med ordered)Decreases platelet aggregation, indicated for prevention of DVT/PE

Nursing Implications (what to focus on) Contraindications/warnings/interactionsHypersensitivity to aspirin, tartrazine (FDC yellow dye #5), or other salicylatesCross-sensitivity with other NSAIDs may exist (less with nonaspirin salicylates)Bleeding disorders or thrombocytopenia (more important with aspirin)Common side effectsdyspepsia, epigastric distress, heartburn, nausea

Interactions with other patient drugs, OTC or herbal medicines (ask patient specifically)

Lanoxin (may increase the risk for bleeding)

Lab value alterations caused by medicineMay cause ↑ serum AST, ALT, and alkaline phosphatase, especially when plasma concentrations exceed 25 mg/100 ml. May alter results of serum uric acid, urine vanillylmandelic acid (VMA), protirelin-induced thyroid-stimulating hormone (TSH), urine hydroxyindoleacetic acid (5-HIAA) determinations, and radionuclide thyroid imaging. May cause ↓ serum potassium and cholesterol concentrations.Be sure to teach the patient the following about this medicationAdvise patients receiving aspirin prophylactically to take only prescribed dose. Increasing the dose has not been found to provide additional benefits. Instruct patient to take salicylates with a full glass of water and to remain in an upright position for 15-30 min after administration.

Nursing Process- Assessment(Pre-administration assessment)Patients who have asthma, allergies, and nasal polyps or who are allergic to tartrazine are at an increased risk for developing hypersensitivity reactions

AssessmentWhy would you hold or not give this med?onset of tinnitus, headache, hyperventilation, agitation, mental confusion, lethargy, diarrhea, and sweating.

EvaluationCheck after givingPrevention of DVT/PE